SG Americas Securities LLC Reduces Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

SG Americas Securities LLC decreased its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 27.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,150 shares of the company’s stock after selling 9,520 shares during the quarter. SG Americas Securities LLC’s holdings in Ventyx Biosciences were worth $55,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Vestal Point Capital LP lifted its holdings in Ventyx Biosciences by 31.2% in the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after acquiring an additional 410,000 shares during the period. Barclays PLC lifted its holdings in Ventyx Biosciences by 273.1% in the third quarter. Barclays PLC now owns 80,295 shares of the company’s stock valued at $175,000 after acquiring an additional 58,776 shares during the period. Sio Capital Management LLC lifted its holdings in Ventyx Biosciences by 153.2% in the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after acquiring an additional 1,193,024 shares during the period. State Street Corp lifted its holdings in Ventyx Biosciences by 0.8% in the third quarter. State Street Corp now owns 1,187,650 shares of the company’s stock valued at $2,589,000 after acquiring an additional 9,783 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Ventyx Biosciences by 2.0% in the third quarter. JPMorgan Chase & Co. now owns 1,007,519 shares of the company’s stock valued at $2,196,000 after acquiring an additional 20,236 shares during the period. Institutional investors own 97.88% of the company’s stock.

Wall Street Analysts Forecast Growth

VTYX has been the topic of a number of recent research reports. Oppenheimer reissued an “outperform” rating and issued a $9.00 target price (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. HC Wainwright reissued a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Ventyx Biosciences currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Insider Transactions at Ventyx Biosciences

In related news, insider John Nuss sold 13,161 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the sale, the insider now owns 485,701 shares of the company’s stock, valued at approximately $1,097,684.26. This trade represents a 2.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Raju Mohan bought 238,248 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were acquired at an average cost of $1.83 per share, for a total transaction of $435,993.84. Following the purchase, the chief executive officer now directly owns 1,913,276 shares in the company, valued at $3,501,295.08. This trade represents a 14.22 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 630,000 shares of company stock valued at $1,262,415 over the last quarter. 18.18% of the stock is currently owned by company insiders.

Ventyx Biosciences Stock Up 3.7 %

NASDAQ VTYX opened at $1.68 on Friday. The stock’s 50-day moving average price is $2.18 and its 200-day moving average price is $2.19. Ventyx Biosciences, Inc. has a 52 week low of $1.57 and a 52 week high of $11.48. The company has a market capitalization of $118.79 million, a P/E ratio of -0.71 and a beta of 0.52.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.